Drug Insights

Unveiling Pseudoephedrine: How to Search for it on Synapse

18 March 2024
2 min read

Pseudoephedrine Hydrochloride, a small molecule drug, acts as an α-adrenergic receptor agonist, exerting its effects through the stimulation of α-adrenergic receptors. The drug, first approved in August 1975, is primarily utilized as a decongestant to alleviate nasal congestion caused by a variety of factors, such as the common cold, allergies, or sinusitis. Pseudoephedrine Hydrochloride operates by eliciting a response from the α-adrenergic receptors present in the smooth muscle of the blood vessels located in the nasal passages, inducing constriction and mitigating the swelling of the nasal mucosa. This process culminates in an augmented airflow through the nasal passages, relieving congestion. However, owing to its potential for abuse and the production of illegal drugs, pseudoephedrine-containing medications are currently subject to strict regulation and require a prescription in numerous countries to prevent their misuse. Click on the image below to begin the exploration journey of Pseudoephedrine through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Silence Therapeutics' Zerlasiran Shows Promise in Phase 2 Trial for High Lipoprotein(a)
Latest Hotspot
3 min read
Silence Therapeutics' Zerlasiran Shows Promise in Phase 2 Trial for High Lipoprotein(a)
15 March 2024
Silence Therapeutics Reveals Encouraging Preliminary Results at 36 Weeks from Active Phase 2 Trial with Zerlasiran in Subjects with Elevated Lipoprotein(a) Levels.
Read →
Development of CCR8 Antibodies as a Hot Target for Immuno-Oncology Therapy in Solid Tumors
Development of CCR8 Antibodies as a Hot Target for Immuno-Oncology Therapy in Solid Tumors
15 March 2024
Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.
Read →
Takeda's Phase 2 Results for Anti-CD38 Antibody Mezagitamab (TAK-079) Show Promise in Immune Thrombocytopenia Treatment
Latest Hotspot
3 min read
Takeda's Phase 2 Results for Anti-CD38 Antibody Mezagitamab (TAK-079) Show Promise in Immune Thrombocytopenia Treatment
15 March 2024
Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.
Read →
Expert Tips for Searching Doxepin on Synapse
Drug Insights
2 min read
Expert Tips for Searching Doxepin on Synapse
15 March 2024
Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.